MLYS NASDAQ
Mineralys Therapeutics, Inc.
1W: -2.1%
1M: -17.6%
3M: -19.8%
YTD: -40.8%
1Y: -47.0%
3Y: +152.8%
$21.13
+0.57 (+2.77%)
Weekly Expected Move ±8.1%
$17
$19
$21
$22
$24
Credit Risk of going bust: lower than 59% of companies Debt: 5.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.14 (down 99.4%), Mineralys Therapeutics, Inc. would be worth roughly what it owes.
Total debt $97.6M against a stock market value of $1.87B.
Distance to default 6.09 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $48.8M (short-term plus half of long-term), stock volatility 59.6%; Altman Z'' 4.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.14 (down 99.4%), Mineralys Therapeutics, Inc. would be worth roughly what it owes.
Total debt $97.6M against a stock market value of $1.87B.
Distance to default 6.09 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $48.8M (short-term plus half of long-term), stock volatility 59.6%; Altman Z'' 4.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9B
52W Range20.12-47.65
Volume3,199,793
Avg Volume1,184,417
Beta0.69
Dividend—
Analyst Ratings
Company Info
CEOJon Congleton
Employees76
SectorHealthcare
IndustryBiotechnology
IPO Date2023-02-10
Websitemineralystx.com
150 N. Radnor Chester Rd.
Radnor, PA 19087
US
Radnor, PA 19087
US
888-378-6240
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Latest News
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
Mineralys (NASDAQ: MLYS) CEO sells 75,000 shares under prearranged plan
Mineralys Therapeutics (NASDAQ:MLYS) Stock: Insider Jon Congleton Sells 75,000 Shares
Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company Stock
Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Peterson Kristine | A-Award | 12,400 | — | 2026-10-19 |
| Peterson Kristine | A-Award | 16,600 | $20.92 | 2026-10-19 |
| Peterson Kristine | 0 | — | 2026-10-19 | |
| COATS LONNEL | A-Award | 12,400 | — | 2026-10-19 |
| COATS LONNEL | A-Award | 16,600 | $20.92 | 2026-10-19 |